Trial Profile
A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs SCT 200 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Sinocelltech
- 28 Oct 2022 Results (n=56; From December 16, 2014 to December 31, 2018) assessing the safety, tolerability, pharmacokinetics and efficacy of SCT200 in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer, published in the BMC Cancer.
- 08 Apr 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.
- 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.